Clinical Trial: Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational



Official Title: Revlimid® Capsules Drug Use-results Surveillance Relapsed or Refractory Adult T-cell Leukemia Lymphoma

Brief Summary:

To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory Adult T-cell Leukemia Lymphoma (ATLL)).

  1. Planned registration period 3 years
  2. Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL